Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
説明 | Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis. |
ターゲット&IC50 | Hepsin:0.33 μM |
In vitro | Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage[1]. |
In vivo | HepIn-13 displays dose-dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes in LPB-Tag/PB-Hepsin mice and blocks prostate cancer metastasis in this animal model. |
別名 | Hepln 13, Hepln13 |
分子量 | 325.2 |
分子式 | C17H13BrN2 |
CAS No. | 64369-13-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (184.50 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Hepln-13 64369-13-7 Tyrosine Kinase/Adaptors c-Met/HGFR potent non-toxic overexpression-relevant phenotypes orally inhibit Hepln 13 prostate cancer Inhibitor Hepln13 inhibitor